Article
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.
Leukemia - 1 May 2015
Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky W E, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus C D, Ho A D, Neubauer A, Serve H, Mayer J, Berdel W E, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G
Abstract excerpt
The optimal timing of allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) is controversial. We report on 1179 patients with a median age of 48 years who were randomized upfront. In the control arm, sibling HCT was scheduled in the first complete remission for intermediate-risk or high-risk AML and matched unrelated HCT in complex karyotype AML. In the experimental arm, matched...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.